163 related articles for article (PubMed ID: 36450385)
21. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.
Tong TML; Burgmans MC; Speetjens FM; van Erkel AR; van der Meer RW; van Rijswijk CSP; Jonker-Bos MA; Roozen CFM; Sporrel-Blokland M; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Kapiteijn E
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):350-359. PubMed ID: 36624292
[TBL] [Abstract][Full Text] [Related]
22. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
24. Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.
Potluri R; Ranjan S; Bhandari H; Johnson H; Moshyk A; Kotapati S
Exp Hematol Oncol; 2019; 8():14. PubMed ID: 31312536
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T; Leung CH; Weissferdt A; Pataer A; Carter BW; Godoy MCB; Feldman H; William WN; Xi Y; Basu S; Sun JJ; Yadav SS; Rojas Alvarez FR; Lee Y; Mishra AK; Chen L; Pradhan M; Guo H; Sinjab A; Zhou N; Negrao MV; Le X; Gay CM; Tsao AS; Byers LA; Altan M; Glisson BS; Fossella FV; Elamin YY; Blumenschein G; Zhang J; Skoulidis F; Wu J; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Rajaram R; Antonoff MB; Fujimoto J; Solis LM; Parra ER; Haymaker C; Wistuba II; Swisher SG; Vaporciyan AA; Lin HY; Wang J; Gibbons DL; Jack Lee J; Ajami NJ; Wargo JA; Allison JP; Sharma P; Kadara H; Heymach JV; Sepesi B
Nat Med; 2023 Mar; 29(3):593-604. PubMed ID: 36928818
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
Mandala M; Larkin J; Ascierto PA; Del Vecchio M; Gogas H; Cowey CL; Arance A; Dalle S; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Lutzky J; De La Cruz-Merino L; Atkinson V; Arenberger P; Hill A; Fecher L; Millward M; Khushalani NI; de Pril V; Lobo M; Weber J
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452930
[TBL] [Abstract][Full Text] [Related]
29. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A
Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733
[TBL] [Abstract][Full Text] [Related]
30. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
32. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
Yusko E; Vignali M; Wilson RK; Mardis ER; Hodi FS; Horak C; Chang H; Woods DM; Robins H; Weber J
Cancer Immunol Res; 2019 Mar; 7(3):458-465. PubMed ID: 30635271
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
34. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Gibney GT; Kudchadkar RR; DeConti RC; Thebeau MS; Czupryn MP; Tetteh L; Eysmans C; Richards A; Schell MJ; Fisher KJ; Horak CE; Inzunza HD; Yu B; Martinez AJ; Younos I; Weber JS
Clin Cancer Res; 2015 Feb; 21(4):712-20. PubMed ID: 25524312
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
[TBL] [Abstract][Full Text] [Related]
36. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM
Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Schenk KM; Deutsch JS; Chandra S; Davar D; Eroglu Z; Khushalani NI; Luke JJ; Ott PA; Sosman JA; Aggarwal V; Schollenberger MD; Sharfman WH; Bibee KP; Scott JF; Loss MJ; Wang H; Qi H; Sharon E; Streicher H; Chen HX; Woodward RN; Bagnasco SM; Taube JM; Topalian SL; Brennan DC; Lipson EJ
J Clin Oncol; 2024 Mar; 42(9):1011-1020. PubMed ID: 38252910
[TBL] [Abstract][Full Text] [Related]
38. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Duerinck J; Schwarze JK; Awada G; Tijtgat J; Vaeyens F; Bertels C; Geens W; Klein S; Seynaeve L; Cras L; D'Haene N; Michotte A; Caljon B; Salmon I; Bruneau M; Kockx M; Van Dooren S; Vanbinst AM; Everaert H; Forsyth R; Neyns B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168003
[TBL] [Abstract][Full Text] [Related]
39. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.
Johannet P; Liu W; Fenyo D; Wind-Rotolo M; Krogsgaard M; Mehnert JM; Weber JS; Zhong J; Osman I
Clin Cancer Res; 2022 Sep; 28(18):4121-4130. PubMed ID: 36106402
[TBL] [Abstract][Full Text] [Related]
40. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
Saad M; Lee SJ; Tan AC; El Naqa IM; Hodi FS; Butterfield LH; LaFramboise WA; Storkus W; Karunamurthy AD; Conejo-Garcia J; Hwu P; Streicher H; Sondak VK; Kirkwood JM; Tarhini AA
J Transl Med; 2022 Jun; 20(1):253. PubMed ID: 35659704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
